Nov a S		Sheet 1 01 3
Substitute Form P30-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office	Attorney's Docket No. 06275-150003	Application No. 10/010,283
Information Diese Sure Statement by Applicant	Applicant Carl-Axel Bauer et al.	
(Use several sheets if necessary) (37 CFR §1.98(b))	Filing Date November 13, 2001	Group Art Unit 1617

			U.S. Paten	t Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	BA						

	Foreign Patent Documents or Published Foreign Patent Applications						
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes No 4
	BB	WO 97/11783	04/03/1997	WIPO			

(Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.			
Initial	ID	Document		
	BC /	"American Thoracic Society: Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease," Am. J. Respir. Care Med. 152:S77-S121 (1995)		
	$\mathrm{BD}_{_{x}}$	"Atemstillstand" Pschyrembel Klinisches Wörtebuch (2002) (in German)		
	BE'	Auffarth et al., "Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease" <i>Thorax</i> 46:372-377 (1991)		
	BF,	Barnes, "Inhaled steroids in COPD" The Lancet 351:766-767 (1998)		
	BĢ	Basic Reference Manual, vol. 1, revised ed. of 1988, issued by IMS International		
	ВӉ	"Bronchodilators and anti-inflammatories," <i>Monthly Index of Medical Specialities (MIMS)</i> 242-256 (09/1997)		
	BI	Boyd et al., "An Evaluation of Salmeterol in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)," Eur. Resp. J. 10:815-821 (1997)		
	ВĴ	Burge et al. "Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial," British Med. J. 320:1297-1303 (2000)		
	BK	Davies et al., "Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease," Q. J. Med. 92:395-400 (1999)		
	BL	"Disorders of the Airways," Current Medical Diagnosis and Treatment 1997 36th ed. pages 241-255, Stamford, CT: Appleton and Lange (1997)		
	BM	Dompeling <i>et al.</i> , "Slowing the deterioration of Asthma and Chronic Obstructive Pulmonary Disease Observed during Bronchodilator Therapy by Adding Inhaled Corticosteroids," <i>Ann. Intern. Med.</i> 118(10):770-778 (1993)		
	BN	Engel et al., "A trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis" Eur. Respir. J. 2:935-939 (1989)		
	ВО	Fabbri et al., "Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update" Eur. Respir. J. 22:1-2 (2003)		
	BP	Flenley, "Chronic Obstructive Pulmonary Disease," Disease-A-Month 34:549-599 (1988)		
	BQ	"Foradil" Compendium Suisse des Medicaments, Supplement 1a pages 7-8 (1991) (in French)		

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	ot in conformance and not considered. Include copy of this form with
next communication to applicant.	

7		
Substitute Form PTO-14480V 0 2005 S. Department of Commerce (Modified) Patent and Trademark Office	Attorney's Docket No. 06275-150003	Application No. 10/010,283
Information Disclosure Statement	Applicant Carl-Axel Bauer et al.	
(Use several sheets if necessary) (37 CFR \$1.98(b))	Filing Date November 13, 2001	Group Art Unit 1617

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
	BR	"Foradil," Compendium Suisse des Medicaments, 15th Ed. 1997/1998, Ed. Grand Public, compiled June 1996, pages 419-420, 866 (in French)
	BS	"Foradil," Compendium Suisse des Medicaments, 18th Ed. 1997, compiled June 1996, pages 849-850 and 1635 (in French)
	ВТ	"Foradil" Patient information leaflet, published by IKS, Switzerland (12/1990) (in French)
	BU	Gibson et al., Respiratory Medicine Table of contents (2002)
	BV	"GOLD: Global Initiative for Chronic Obstructive Lung Disease," Executive Summary; National Institutes of Health, National Heart Lung and Blood Institute, NIH Publication No. 2701A, pages 1-30 (03/2001)
	BW	"GOLD: Global Initiative for Chronic Obstructive Lung Disease; Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease," based on April 1998 NHLBI/WHO Workshop, pages 1-100 (2004 Update)
	BX	Jeffery "Structural and inflammatory changes in COPD: a comparison with asthma" <i>Thorax</i> 53:129-136 (1998)
	BY	Keatings et al., "Effects of Inhaled and Oral Glucocorticoids on Inflammatory Indices in Asthma and COPD" Am. J. Respir. Crit. Care Med. 155:542-548 (1997)
	BZ	Kerstjens et al., "A Comparison of Bronchodilator Therapy with or without Inhaled Corticosteroid Therapy for Obstructive Airways Disease," New Eng. J. Med. 327:1413-1419 (1992)
	BAA	Leff et al., "Therapeutic Regimens in Chronic Obstructive Pulmonary Disease," Pulmon. Crit. Care Pharmacol. Therapeut. Ch. 86:837-844 (1996)
	BBB	Niewoehner et al., "Effect of Systemic Glucocorticoids on Exacerbations of Chronic Obstructive Pulmonary Disease" New Eng. J. Med. 340(25):1941-1947 (1999)
	BCC	Norman, "COPD: New Developments and Therapeutic Opportunities" <i>Drug News Perpect</i> . 11(7):431-437 (1998)
	BDD	Pauwels et al., "Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking" N. Eng. J. Med. 340:1948-1953 (1999)
	BEE	Postma, "Inhaled therapy in COPD: what are the benefits?" Respiratory Medicine 85:447-449 (1991)
	BFF	"Pulmicort" ABPI Data Sheet Compendium, p. 146-147 (1995/1996)
	BGG	Schultze-Werninghaus, "Multicenter 1-Year Trial on Formoterol, a New Long-Acting β ₂ -Agonist, in Chronic Obstructive Airway Disease," <i>Lung</i> Suppl:83-89 (1990)
	внн	Siafakas et al., "Optimal Assessment and Management of Chronic Obstructive Pulmonary Disease (COPD)," Eur. Respir. J. 8:1398-1420 (1995)
	BII	Soriano et al., "Inhaled Corticosteroids with/Without Long-Acting b-Agonists Reduce the Risk of Rehospitalization and Death in COPD Patients," Am. J. Respir. Medic. 2:67-74 (2003)
	ВЈЈ	Stalenheim et al., "Efficacy and Tolerance of a 12-Week Treatment with Inhaled Formoterol in Patients with Reversible Obstructive Lung Disease," Respiration 61:305-309 (1994)
	BKK	Stedman's Medical Dictionary, 25th ed., Baltimore: Williams and Wilkins; page 428
	BLL	Szafranski et al., "Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease" Eur. Respir. J. 21:74-81 (2003)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant	t in conformance and not considered. Include copy of this form with

Sheet	3	of	3

Substitute Form PTO-14492 NUV C.U. an Department of Commerce (Modified)

Information Disclosure Statement by Application No. 10/010,283

Applicant Carl-Axel Bauer et al.

(Use several sheets if necessary)

Attorney's Docket No. 06275-150003 10/010,283

Applicant Carl-Axel Bauer et al.

Filing Date Group Art Unit November 13, 2001 1617

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document			
	ВММ	Trechsel, "Foradil in medical practice; 7 case studies" Ciba Geigy (1992)			
	BNN	Van Schayck et al., "Do patients with COPD benefit from treatment with inhaled corticosteroids?" Eur. Respir. J. 9:1969-1972 (1996)			
	воо	Vestbo et al., "Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial," Lancet 353:1819-1823 (1999)			
	ВРР	Watson et al., "Failure of Inhaled Corticosteroids to Modify Bronchoconstrictor or Bronchodilator Responsiveness in Middle-Aged Smokers with Mild Airflow Obstruction" Chest 101(2):350-355 (1992)			
	BQQ	Weiner et al., "Inhaled Budesonide Therapy for Patients with Stable COPD," Chest 108:1568-1571 (1995)			

Examiner Signature Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.